Patents by Inventor Chuo Chen

Chuo Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY
    Publication number: 20200308216
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN
  • Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
    Patent number: 10696710
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: June 30, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY
    Publication number: 20200140477
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Application
    Filed: December 13, 2019
    Publication date: May 7, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN
  • Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
    Patent number: 10633411
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: April 28, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY
    Publication number: 20200102342
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Application
    Filed: November 18, 2019
    Publication date: April 2, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20200010501
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Application
    Filed: June 11, 2019
    Publication date: January 9, 2020
    Applicants: ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
    Inventors: Boyu ZHONG, Heping SHI, Yuanwei DAI, Qi WEI, Chuo CHEN, Zhijian CHEN, Lijun SUN
  • Cyclic di-nucleotide compounds and methods of use
    Patent number: 10519188
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Grant
    Filed: April 15, 2018
    Date of Patent: December 31, 2019
    Assignees: ImmuneSensor Therapeutics, Inc., The Board of Regents of the University of Texas System
    Inventors: Boyu Zhong, Lijun Sun, Heping Shi, Qi Wei, Yuanwei Dai, Chuo Chen, Zhijian Chen
  • Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
    Patent number: 10508129
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: December 17, 2019
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof
    Patent number: 10420758
    Abstract: The present disclosure provides compounds that may be useful for inhibiting the Tankyrase enzyme. In some aspects, these compounds are useful in the treatment of a disease or disorder related to the misregulation of Tankyrase enzyme such as cancer, degenerative diseases, or fibrotic diseases. Also provided herein are compounds may also be used to prevent the elongation of the telomere in a cell.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: September 24, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Chuo Chen, Xuewu Zhang, Ozlem Kulak, Xiaofeng Wu
  • PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY
    Publication number: 20190263851
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies, and diagnostics.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Applicant: Board of Regents, The University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN
  • DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS
    Publication number: 20190202804
    Abstract: The present disclosure provides compounds that may be useful for inhibiting Wnt pathway comprising compounds of the formula: (Ia) or (Ib) wherein the variables are as defined herein. In some aspects, the compounds may be used to inhibit the Wnt pathway and used to treat cancer, myocardial infarction, osteopetrosis, or used in the maturation of a precursor cell to a mature cell. Also provided herein in are pharmaceutical compositions of the compounds described herein.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 4, 2019
    Inventors: Nageswari YARRAVARAPU, Chuo CHEN, Lawrence LUM, Lin YOU, Chengwei ZHANG, Xiaolei WANG, Lishu ZHANG
  • Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
    Patent number: 10336786
    Abstract: Cyclic-GMP-AMP synthase (cGAS) and cyclic-GMP-AMP (cGAMP), including 2?3-cGAMP, 2?2-cGAMP, 3?2?-cGAMP and 3?3?-GAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: July 2, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhijian Chen, Lijun Sun, Jiaxi Wu, Heping Shi, Chuo Chen
  • INDOLINYL-SULFONAMIDE INHIBITORS OF TANKYRASE AND METHODS OF USE THEREOF
    Publication number: 20180271848
    Abstract: The present disclosure provides compounds that may be useful for inhibiting the Tankyrase enzyme. In some aspects, these compounds are useful in the treatment of a disease or disorder related to the misregulation of Tankyrase enzyme such as cancer, degenerative diseases, or fibrotic diseases. Also provided herein are compounds may also be used to prevent the elongation of the telomere in a cell.
    Type: Application
    Filed: May 2, 2016
    Publication date: September 27, 2018
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence LUM, Chuo CHEN, Xuewu ZHANG, Ozlem KULAK, Xiaofeng WU
  • CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20180230177
    Abstract: Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.
    Type: Application
    Filed: April 15, 2018
    Publication date: August 16, 2018
    Inventors: Boyu ZHONG, Lijun SUN, Heping SHI, Qi WEI, Yuanwei DAI, Chuo CHEN, Zhijian CHEN
  • cGAS ANTAGONIST COMPOUNDS
    Publication number: 20180230115
    Abstract: Disclosed are novel compounds of Formula I that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
    Type: Application
    Filed: April 15, 2018
    Publication date: August 16, 2018
    Inventors: Boyu ZHONG, Lijun SUN, Heping SHI, Jing Li, Chuo CHEN, Zhijian CHEN
  • NOVEL COMPOUNDS SUPPORTS HEMATOPOIETIC STEM CELLS AND RED BLOOD CELLS
    Publication number: 20170304240
    Abstract: The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythropoietin in patients to mitigate the side effects of erythropoietin.
    Type: Application
    Filed: May 12, 2015
    Publication date: October 26, 2017
    Inventors: Chengcheng ZHANG, Yi LIU, Junke ZHENG, Mi DENG, Chuo CHEN, Jiawei LIU
  • Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
    Publication number: 20170296655
    Abstract: Cyclic-GMP-AMP (cGAMP), including 2?,3?-cGAMP, are used in pharmaceutical formulations (including vaccine adjuvants), drug screens, therapies and diagnostics.
    Type: Application
    Filed: January 29, 2017
    Publication date: October 19, 2017
    Applicant: Board of Regents, The University of Texas System
    Inventors: Zhijian CHEN, Lijun SUN, Jiaxi WU, Heping SHI, Chuo CHEN
  • Highly potent inhibitors of porcupine
    Patent number: 9783550
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: October 10, 2017
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Lawrence Lum, Chuo Chen
  • HIGHLY POTENT INHIBITORS OF PORCUPINE
    Publication number: 20160115177
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 28, 2016
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence LUM, Chuo CHEN
  • WNT PROTEIN SIGNALLING INHIBITORS
    Publication number: 20150374696
    Abstract: The present invention generally relates to protein signalling. In particular, compounds that inhibit the Wnt protein signalling pathway are disclosed. Such compounds may be used in the treatment of Wnt protein signalling-related diseases and conditions such as cancer, degenerative diseases, type II diabetes and osteopetrosis.
    Type: Application
    Filed: June 2, 2015
    Publication date: December 31, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Lawrence LUM, Michael G. ROTH, Baozhi CHEN, Chuo CHEN, Michael E. DODGE, Wei TANG